Application of stress particle inducer in preparation of umbilical cord mesenchymal stem cell aging inhibitor
By screening stress particle inducers in hUC-MSCs, using G3BP1 and G3BP2 to induce stress particle formation, the problem of cell aging is solved, the aging process of hUC-MSCs is delayed, and new clinical application strategies are provided, and through isolation isolating PAI-1 reduces aging-related phenotypes and significantly improves cell health status.
Patent Information
- Application Number
- CN202411136421.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-12-06
AI Technical Summary
Human umbilical cord mesenchymal stem cells gradually lose their proliferative ability and therapeutic properties during in vitro expansion, resulting in aging and affecting their clinical application. The existing methods of delaying aging have certain clinical application limitations and side effects.
By screening and verifying stress particle inducers, the stress particle core proteins G3BP1 and G3BP2 that express the detectable tags induced stress particle formation in eukaryotic cells, sodium arsenite and methylbardozolone were screened out, and the stress particle formation was induced by using the stress particle core protein G3BP1 and G3BP2 that carry detectable tags, and the stress particle formation was screened out. The compound acts as a stress particle inducer and inhibits doxorubicin-induced cellular senescence.
The successful delay of the aging of hUC-MSCs provides a new strategy to increase their clinical application, and the induction of stress particles to isolate the aging-related secretory protein PAI-1, improves the cell cycle arrest status and significantly reduces the aging-related phenotype.
Smart Images

Figure CN119082248A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to the application of a stress granule inducer in the preparation of an umbilical cord mesenchymal stem cell aging inhibitor. Background Art
[0002] Human umbilical cord mesenchymal stem cells (hUC-MSCs) refer to a type of multifunctional stem cells present in the umbilical cord tissue of newborns, which have the functions of self-renewal, multidirectional differentiation and immunoregulation. First of all, hUC-MSCs can continuously self-renew and differentiate into one or more cell types under certain conditions, such as osteoblasts, chondrocytes and adipocytes, which then constitute the tissues and organs of the human body. hUC-MSCs cells themselves can also play an immunoregulatory function: intravenously injected hUC-MSCs can migrate to the site of injury and respond to inflammation. In addition, hUC-MSCs can also secrete a variety of bioactive factors through autocrine or paracrine secretion or through extracellular vesicles, such as exosomes and microvesicles, to respond to local microenvironment or signals. Compared with other stem cells, hUC-MSCs have the advantages of being easier to obtain, separate, culture, amplify and purify. And hUC-MSCs have low immunogenicity, so they have more unique advantages in clinical applications. In addition, compared with traditional treatments, hUC-MSCs can not only improve the survival rate, but also significantly improve the various clinical symptoms of the disease. In summary, hUC-MSCs has become one of the important sources of stem cells in cell therapy and regenerative medicine.
[0003] There is increasing evidence that hUC-MSCs have advantages in treating a variety of diseases. However, hUC-MSCs will gradually lose their proliferation ability and therapeutic properties after in vitro expansion. hUC-MSCs can be cultured multiple times and subcultured to obtain a large number of cells. However, during long-term culture, abnormalities in pathways related to the cell cycle and DNA damage response can lead to genomic instability in hUC-MSCs, and in the later stages of subculture, the cell morphology becomes longer and larger, proliferation slows, and proliferation-related genes decrease. The aging of hUC-MSCs will affect their clinical application. For example, in the treatment of acute liver failure, the 5th generation cells are more effective than the 10th generation cells in homing to the liver, enhancing liver cell proliferation, and inhibiting apoptosis. And the elimination of senescent cells can promote stem cell proliferation and delay the appearance of aging characteristics.
[0004] hUC-MSCs aging is a complex problem that requires a variety of different approaches to alleviate or prevent aging and improve the clinical application of hUC-MSCs. Currently, there are three main methods to reverse or delay hUC-MSCs cell aging and maintain their in vitro proliferation capacity: gene modification, microRNA treatment, and pretreatment modification. Gene modification includes two types of gene reprogramming: complete reprogramming by recoding intracellular genes to reset epigenetics and partial reprogramming by DNA methylation and histone modification to make epigenetics younger. MicroRNA delays hUC-MSCs aging through multidimensional targets. Pretreatment modification refers to the in vitro treatment of cells with chemical and physical factors through a specially designed environment. Pretreatment modification can improve the interaction between cells and the immune system. However, the three existing methods for delaying hUC-MSCs aging all have certain clinical application limitations. First, the key pathway factors that regulate hUC-MSCs aging are also important physiological regulators of normal biological functions. Intervention to completely inhibit or activate these pathways may have other negative effects. Second, one or two microRNAs have little effect in delaying hUC-MSCs aging treatment, and several aging-related microRNAs need to be used in combination to exert therapeutic functions. Therefore, it is necessary to find an effective method to delay hUC-MSCs that is relatively safe to the body, so as to increase and promote the clinical application of hUC-MSCs.
[0005] Stress granules (SGs) refer to dynamic complex aggregates of mRNA and proteins formed when cells are stimulated by external stimuli (such as heat shock, oxidative stress, and viral infection). SGs are composed of mRNA and various RNA-binding proteins, including G3BP1 and Caprin1, which are considered to be central scaffold proteins required for multivalent interactions and SGs assembly. Senescent cells can also form SGs under conditions of oxidative stress, and recent literature has shown that there is a new interaction between aging and SGs, and SGs can affect the aging process and the behavior of senescent cells. SGs induced in senescent cells can play a role in delaying aging by isolating the aging-related factor PAI-1. PAI-1 is not only a marker of cell aging, but also a key mediator of cell aging. PAI-1 prevents Rb from phosphorylating on Cyclin D1 (CycD1) through autocrine function, leading to cell growth arrest. In addition, senescence-inducing signals, such as DNA damage response and oxidative stress, can induce the activation of the tumor suppressor p53. p53 interferes with CycD1-dependent RB phosphorylation by promoting the expression and secretion of PAI-1, leading to irreversible cell cycle arrest. In addition, there are literatures showing that overexpression of PAI-1 can lead to premature aging in mice, but inhibiting the production of PAI-1 can reverse this phenotype. When senescent cells are exposed to oxidative stress, the formation of SGs is induced, and PAI-1 is recruited to isolate and enter SGs. When SGs are induced to isolate PAI-1, the transport of CycD1 to the nucleus can be increased, thereby promoting RB phosphorylation and improving the arrested state of the cell cycle. Therefore, intervention in SGs may become a new strategy to delay stem cell aging. However, the method of inducing SGs in hUC-MSCs, the effect of SGs inducers on hUC-MSCs aging and its mechanism of action are still unclear. Summary of the invention
[0006] The present invention explores the method of delaying hUC-MSCs aging by successfully establishing an hUC-MSCs aging model. Experiments show that the SGs inducers screened out from hUC-MSCs can delay hUC-MSCs aging by inducing SGs to sequester aging-related secretory proteins, providing a new strategy for delaying stem cell aging and increasing the clinical application of stem cells.
[0007] The specific technical solutions of the present invention are as follows:
[0008] The present invention aims to provide the use of a stress granule inducer in the preparation of an umbilical cord mesenchymal stem cell aging inhibitor, wherein the stress granule inducer is obtained by screening eukaryotic cells expressing stress granule core proteins G3BP1 and / or G3BP2 carrying detectable labels.
[0009] Preferably, the detectable label is a fluorescent protein selected from green fluorescent protein (GFP), red fluorescent protein (RFP, mCherry) or yellow fluorescent protein (YFP, Venus).
[0010] The eukaryotic cells expressing the stress granule core proteins G3BP1 and / or G3BP2 carrying detectable labels of the present invention are prepared by the following method:
[0011] (1) inserting a G3BP1 or G3BP2 nucleotide fragment carrying a detectable tag into the pSin-EF2 vector to construct an expression plasmid;
[0012] (2) The expression plasmid is packaged into lentivirus and transfected into eukaryotic cells.
[0013] Preferably, the eukaryotic cells are HeLa cells, HEK293T cells or U2OS cells.
[0014] When HeLa cells are used as eukaryotic cells, the HeLa cells transfected with the expression plasmid in step (2) can be screened and amplified using the lowest lethal concentration of puromycin to obtain a stable cell line.
[0015] In a specific example of the present invention, the model is a HeLa cell expressing GFP-G3BP1 or GFP-G3BP2. It is constructed by the following method:
[0016] (1) Design and synthesize the following primers for amplifying GFP-G3BP1 or GFP-G3BP2:
[0017] Primers for amplification of GFP-G3BP1:
[0018] EGFP-Cla-F: 5'-gcaATCGATATGgtgagcaagggcgaggag-3'.
[0019] hG3BP1-Mlu-R: 5'-agtACGCGTtTCActgccgtggcgcaagcc-3'.
[0020] Primers for amplification of GFP-G3BP2:
[0021] EGFP-Cla-F: 5'-gcaATCGATATGgtgagcaagggcgaggag-3'.
[0022] hG3BP2-Mlu-R: 5'-agtACGCGTTCAgcgacgctgtcctgtgaa-3'.
[0023] (2) Using pCS2-GFP-G3BP1 or pCS2-GFP-G3BP2 as template and the above primers, high-fidelity Q5 polymerase was used to PCR amplify the DNA fragment encoding the GFP-G3BP1 or GFP-G3BP2 fusion protein.
[0024] (3) PCR conditions were as follows: denaturation at 98°C for 2 min; 30 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 70 s; and extension at 72°C for 5 min. The PCR products of GFP-G3BP1 or GFP-G3BP2 were purified and cloned into the pSin-EF2 vector to obtain the pSin-EF2-GFP-G3BP1 plasmid and the pSin-EF2-GFP-G3BP2 plasmid.
[0025] (4) adding pSin-EF2-GFP-G3BP1 or pSin-EF2-GFP-G3BP2 plasmid, ΔR virus packaging plasmid and VSVG virus envelope plasmid to serum-free OPTI-MEM medium, mixing evenly, and then adding transfection reagent and mixing evenly;
[0026] (5) Add the mixture containing the plasmid and transfection reagent to 293T cells, change the medium (10% FBS without antibiotics) after about 5-6 hours, continue culturing for about 48 hours, collect the supernatant, and use it to infect cells or store it in a 4°C refrigerator for later use;
[0027] (6) Add the viral transfection solution of step (4) to HeLa cells and culture them in a 37° C., 5% CO 2 incubator for 24 hours. The operation can be repeated and the infection can be continued for another 24 hours.
[0028] (7) HeLa cells were digested and cultured for 24 hours after attachment. The cells were selected using the lowest lethal concentration of puromycin. After the cells were fully grown, they were passaged (the first passage required a long time, and subsequent passages were performed approximately every 3 days). The cells were selected for approximately 2-3 weeks to obtain HeLa / GFP-G3BP1 cell lines stably transfected with GFP-G3BP1 and HeLa / GFP-G3BP2 cell lines stably transfected with GFP-G3BP2.
[0029] The puromycin resistance concentration screening method is as follows:
[0030] Considering that each cell line responds differently to puromycin selection, the optimal puromycin concentration for the cell line was determined before the experiment. (1) On day 1, HeLa cells were cultured in 12-well plates and grown overnight at 37°C and 5% CO2.
[0031] (2) On the second day, when the HeLa cells grew to about 80-90%, culture medium containing different concentrations of puromycin was added to the cells (the final concentration of puromycin should be 1-10 μg / mL, with an increment of 1 μg / mL);
[0032] (3) Starting from the 3rd day, HeLa cells were checked daily and fresh culture medium containing puromycin was replaced every other day. The lowest concentration of puromycin that caused complete death of HeLa cells after 3-5 days was used for subsequent screening.
[0033] Another object of the present invention is to provide the use of a stress granule inducer in the preparation of an umbilical cord mesenchymal stem cell aging inhibitor, wherein the stress granule inducer is obtained by screening using the model described in the present invention.
[0034] The specific screening process is as follows: add candidate compounds to the model for 1-2 hours, observe whether droplet-shaped fluorescent stress granules are formed in the cells under a fluorescence microscope, and if the added compound can induce the formation of stress granules, the compound is determined to be a stress granule inducer.
[0035] In a specific example of the present invention, the stress granule inducer is selected from one or more of sodium arsenite, geldanamycin, shikonin, plumbagin, fingolimod or zinc pyrithione.
[0036] The model described in the present invention can also be used to screen stress granule inhibitors, specifically, adding an inhibitor candidate compound to a G3BP1 or G3BP2 eukaryotic cell line that stably expresses a tagged protein and treating the cell for 2 hours, then treating the cell with a stress granule inducer for 1 hour, and then observing the formation of stress granules under a fluorescence microscope. If the number of stress granule-positive cells decreases or the number of stress granules in a single cell decreases, the compound is preliminarily determined to be a stress granule inhibitor.
[0037] Advantages of the present invention:
[0038] 1. The present invention can observe the dynamic changes of stress granule assembly and disaggregation continuously and in real time in living cells by stably expressing GFP-G3BP1 or GFP-G3BP2 in eukaryotic cells, which is superior to the immunofluorescence staining method that can only observe stress granules at a single time point after fixing the cells.
[0039] 2. The present invention successfully screened out stress granule inducers using eukaryotic cells that stably expressed GFP-G3BP1 or GFP-G3BP2. The research results of the present invention show that stress granule inducers (such as sodium arsenite / bardoxolone methyl) inhibit doxorubicin-induced hUC-MSCs senescence by inducing stress granules. The research results of the present invention provide a new strategy for delaying hUC-MSCs senescence and increasing the clinical application of hUC-MSCs. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 Stable cell lines HeLa / GFP-G3BP1 and HeLa / GFP-G3BP2 were used as cell models to observe the dynamics of SGs in living cells in real time, including no SGs in untreated cells, SGs assembly after 30 minutes of AS treatment, SGs disaggregation in a small number of cells after 1 hour of AS treatment, and SGs disaggregation in most cells after 30 minutes of AS treatment and 3 hours of AS treatment. The HeLa / GFP cell line was used as a negative control and did not show the dynamic changes of SGs.
[0041] Figure 2 The stable cell line HeLa / GFP-G3BP2 was used as a cell model for screening stress granule inducers. The results were obtained by directly photographing HeLa / GFP-G3BP2 cells 2 hours after each compound was treated with the compound.
[0042] Figure 3 Results of the detection of β-galactosidase (SA-β-gal) activity in hUC-MSCs induced by doxorubicin. (A) SA-β-gal staining results. (B) Statistical graph of SA-β-gal activity detection results.
[0043] Figure 4 The expression of p21 in hUC-MSCs induced by doxorubicin after senescence. (A) Western blotting results. (B) Semi-quantitative analysis of Western blotting results.
[0044] Figure 5 Immunofluorescence staining to detect the expression changes of γH2A.X foci in the nucleus of hUC-MSCs after doxorubicin-induced senescence. (A) γ-H2A.X foci staining results (green). Scale bar: 20μm. (B) Statistical graph of immunofluorescence staining results.
[0045] Figure 6 In order to verify the SGs inducers screened in hUC-MSCs by immunofluorescence staining, some SGs inducers screened in the HeLa / GFP-G3BP2 cell model were selected and their effects of inducing SGs in hUC-MSCs were verified by immunofluorescence staining.
[0046] Figure 7The inhibitory effect of SGs inducers on doxorubicin-induced hUC-MSCs senescence. (A) SA-β-gal detects the effect of different concentrations of sodium arsenite (AS) or bardoxolone methyl (BM) on doxorubicin-induced hUC-MSCs senescence. (B) Statistical graph of SA-β-gal activity detection results. (C) CCK8 detects the cytotoxicity of different concentrations of sodium arsenite combined with doxorubicin on hUC-MSCs. (D) CCK8 detects the cytotoxicity of different concentrations of bardoxolone methyl combined with doxorubicin on hUC-MSCs.
[0047] Figure 8 SGs inducers reduce senescence-related phenotypes in senescent hUC-MSCs. (A) Western blotting results showed that SGs inducers sodium arsenite and bardoxolone methyl inhibited the expression of p21, a senescent cell marker of hUC-MSCs induced by doxorubicin. (B) Statistical graph of Western blotting results. (C) Immunofluorescence staining results showed that SGs inducers sodium arsenite and bardoxolone methyl inhibited γ-H2A.X foci, a senescent cell marker of hUC-MSCs induced by doxorubicin. Scale bar: 20μm. (D) Statistical graph of immunofluorescence staining results.
[0048] Fig. 9 The SGs inducer delayed the senescence of hUC-MSCs by sequestering the pro-senescence secretory protein PAI-1. The results of immunofluorescence staining detected the changes in the subcellular localization of the pro-senescence secretory protein PAI-1 after hUC-MSCs were treated with sodium arsenite and bardoxolone methyl.
[0049] Fig.10 The effect of sodium arsenite and bardoxolone methyl on delaying the senescence of hUC-MSCs depends on their SGs inducer function. (A) The SGs inhibitor ISRIB can inhibit the SGs induction of sodium arsenite / bardoxolone methyl in hUC-MSCs. G3BP1 is used as a marker of stress granules (green). Scale bar: 20μm. (B) SA-β-gal detection of sodium arsenite / bardoxolone methyl delaying doxorubicin-induced hUC-MSCs senescence after the addition of the SGs inhibitor ISRIB. The right side shows the statistics of senescence results. (C) Immunofluorescence detection of sodium arsenite / bardoxolone methyl reducing DNA damage in doxorubicin-induced senescence hUC-MSCs after the addition of the SGs inhibitor ISRIB. The right side shows the statistics of results. γ-H2A.X foci (green). Scale bar: 20μm. DETAILED DESCRIPTION
[0050] The specific steps of the present invention are described below by way of examples, but are not limited to the examples.
[0051] The terms used in the present invention, unless otherwise specified, generally have the meanings commonly understood by those of ordinary skill in the art.
[0052] The present invention will be further described in detail below in conjunction with specific examples and with reference to data. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention in any way.
[0053] In the following examples, various processes and methods not exhaustively described are conventional methods well known in the art.
[0054] Example 1 Construction of a screening model for stress granule inducers or inhibitors
[0055] 1. Based on cloning, the target fragment GFP-G3BP1 or GFP-G3BP2 was constructed into the pSin-EF2 vector to construct the pSin-EF2-GFP-G3BP1 plasmid and the pSin-EF2-GFP-G3BP2 plasmid.
[0056] GFP amino acid sequence: GenBank QUW04954.1.
[0057]
[0058] G3BP1 amino acid sequence: GenBank NP_005745.1.
[0059]
[0060] G3BP2 amino acid sequence: GenBank NP_987101.1.
[0061]
[0062]
[0063] The specific steps are as follows:
[0064] (1) Design and synthesize the following primers for amplifying GFP-G3BP1 or GFP-G3BP2:
[0065] Primers for amplification of GFP-G3BP1:
[0066] EGFP-Cla-F: 5'-gcaATCGATATGgtgagcaagggcgaggag-3'.
[0067] hG3BP1-Mlu-R: 5'-agtACGCGTtTCActgccgtggcgcaagcc-3'.
[0068] Primers for amplification of GFP-G3BP2:
[0069] EGFP-Cla-F: 5'-gcaATCGATATGgtgagcaagggcgaggag-3'.
[0070] hG3BP2-Mlu-R: 5'-agtACGCGTTCAgcgacgctgtcctgtgaa-3'.
[0071] (2) With reference to Molecular Cloning Experiment Guide (4th Edition) (Cold Spring Harbor Laboratory Press / Science Press), pCS2-GFP-G3BP1 and pCS2-GFP-G3BP2 (for the preparation process, see Chinese invention patent ZL202110649944.1) were used as templates, and the above primers were used to amplify the DNA fragment encoding the GFP-G3BP2 fusion protein by PCR using high-fidelity Q5 polymerase.
[0072] (3) PCR conditions were: denaturation at 98°C for 2 min; 30 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 70 s; and extension at 72°C for 5 min. The PCR products of GFP-G3BP1 or GFP-G3BP2 were purified and cloned into the pSin-EF2 vector (BRICS, #SP-2813) to obtain the pSin-EF2-GFP-G3BP1 plasmid and the pSin-EF2-GFP-G3BP2 plasmid, which were then sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing. The sequencing results showed that the plasmids were correct.
[0073] 2. Lentivirus packaging method
[0074] (1) 293T cells were seeded in a 6 cm cell culture dish, and when the density reached 90%, fresh 293T culture medium (DMEM + 10% FBS) without dual antibodies was replaced;
[0075] (2) Mixing lentiviral vector plasmids: Take a 1.5mL centrifuge tube and add 200μL serum-free OPTI-MEM medium, then add the following lentiviral vector plasmids: 2μg pSin-EF2-GFP-G3BP1 or pSin-EF2-GFP-G3BP2 plasmid, 2μg ΔR virus packaging plasmid and 0.4μg VSVG virus envelope plasmid. After mixing, add 6.6μL transfection reagent Lipofect 2000 (DNAμg: Lipofect 2000μL = 1:1.5) to the centrifuge tube, invert to mix, and let stand for 5 minutes, then mix the two and let stand at room temperature for 20 minutes;
[0076] (3) Add the mixed solution containing the plasmid and transfection reagent to 293T cells, change the medium (10% FBS without antibiotics) after about 5-6 hours, continue culturing for about 48 hours, centrifuge the cell culture medium at 3000 rpm for 15 minutes, collect the supernatant, and use it to infect cells or store it in a 4°C refrigerator for later use;
[0077] 3. Puromycin resistance concentration screening
[0078] Each cell line responds differently to puromycin selection; determine the optimal puromycin concentration for your cell line prior to experimentation.
[0079] (1) On day 1, HeLa cells were cultured in 12-well plates and grown overnight at 37°C and 5% CO2.
[0080] (2) On the second day, when the HeLa cells grew to about 80-90%, culture medium containing different concentrations of puromycin was added to the cells (the final concentration of puromycin should be 1-10 μg / mL, with an increment of 1 μg / mL);
[0081] (3) Starting from the 3rd day, HeLa cells were checked daily and fresh culture medium containing puromycin was replaced every other day. The lowest concentration of puromycin that caused complete death of HeLa cells after 3-5 days was used for subsequent screening.
[0082] 4. Lentiviral transfection method
[0083] (1) Prepare a six-well plate and inoculate HeLa cells. When the density grows to 50%-60%, transfection can be performed.
[0084] (2) Aspirate the cell culture medium, add the mixed virus transfection solution (1 mL culture medium + 1 mL virus supernatant + 2 μL 1000× Polybrene), and culture in a 37°C, 5% CO2 incubator for 24 hours;
[0085] (3) Wash the cells with 3 mL of PBS (once), and then infect them again (24 hours);
[0086] (4) After the cells have grown to full growth, digest the cells and transfer them to a 6 cm dish. 24 hours after attachment, use the lowest lethal concentration of puromycin selected in step 3. After the cells have grown to full growth, subculture them (the first subculture takes a long time, and subsequent subcultures are performed approximately every 3 days). After about 2-3 weeks of screening, HeLa / GFP-G3BP1 cell lines stably transfected with GFP-G3BP1 and HeLa / GFP-G3BP2 cell lines stably transfected with GFP-G3BP2 were obtained.
[0087] 5. Validation of the Stress Granule Inducer Screening Model
[0088] HeLa / GFP-G3BP1, HeLa / GFP-G3BP2 cell lines and HeLa / GFP cell line as a control were seeded into 6-well plates. When the cell count reached 70-80%, the cells were left untreated or treated with 200 μM AS for 30 minutes, or treated with 200 μM AS for 30 minutes and then AS was removed for 1 hour or 3 hours, and then images were acquired under a fluorescence microscope. The results are shown in Figure 1 As shown, both HeLa / GFP-G3BP1 and HeLa / GFP-G3BP2 cell lines reflected in real time the dynamic process of SGs assembly after AS treatment and SGs disaggregation during the recovery process, while the HeLa / GFP cell line used as a control did not show dynamic changes in SGs, indicating that HeLa / GFP-G3BP1 and HeLa / GFP-G3BP2 cell lines can be used for the subsequent screening of SGs inducers.
[0089] Example 2 Screening of stress granule inducers
[0090] The screening model constructed in Example 1 was used to screen compounds in the FDA-approved drug library (APEXBIO, #L1021) and the natural product compound library (APEXBIO, #L1039). The HeLa / GFP-G3BP2 cell line was inoculated into a 24-well plate. When the cells reached 70-80%, 10 μM of different drugs were added to treat the HeLa / GFP-G3BP2 cells for 2 hours, and images were obtained under a fluorescence microscope. The results are shown in Figure 2. Figure 2 As shown, some compounds were screened out that could induce the formation of SGs, including Bardoxolone Methyl (BM), Geldanamycin, Shikonin, Plumbagin, Fingolimod and Zinc Pyrithione.
[0091] Example 3 Preparation of hUC-MSCs aging model
[0092] 1. Take a fresh umbilical cord, clean the surface of the umbilical cord with PBS containing double antibodies, and squeeze out the residual blood in the blood vessels;
[0093] 2. Use sterile surgical scissors to cut off both ends of the umbilical cord and cut the remaining part into small pieces of 2-3 cm in length;
[0094] 3. Continue to wash the umbilical cord with PBS and use tweezers to clean the blood in the umbilical cord;
[0095] 4. Use forceps to peel off the umbilical cord tissue, use hooked forceps to gently tear off the vein, then tear off the artery, then wash it 3 times with PBS, and cut it into pieces in a 50mL centrifuge tube;
[0096] 5. Digest with 0.1% collagenase and hyaluronidase for 3-4 hours, filter, and centrifuge 2-3 times;
[0097] 6. Transfer the cells into a culture flask, spread them evenly, and use DMEM / F12 (1:1) culture medium (Shanghai Yuanpei Biotechnology Co., Ltd.) containing 10% fetal bovine serum for adherent subculture.
[0098] 7. Inoculate hUC-MSCs into a 6-well plate and observe under a microscope. When the cell growth density reaches about 60% to 70%, senescence induction can be performed;
[0099] 8. Take out the cell culture dish, discard the culture medium, wash once with 1×PBS buffer, and add fresh culture medium. Add a certain concentration of doxorubicin to the cells, shake the cell culture dish slightly up and down and left and right to mix evenly, so that the concentration of doxorubicin in the culture medium is 0.05μM. Move to a carbon dioxide cell culture incubator and culture for 48 hours, discard the medium containing drugs, and add fresh complete cell culture medium. Continue to place in a carbon dioxide cell culture incubator to resume culture for 6 days.
[0100] The senescence of hUC-MSCs was detected using the SA-β-gal staining kit. The cells were observed and photographed under a total internal reflection fluorescence microscope, and the number of stained cells in each group was counted. Figure 3 The results showed that hUC-MSCs cells showed obvious senescence.
[0101] The total protein of hUC-MSCs was extracted. Western blotting was used to detect the expression changes of p21, a senescent cell marker, in doxorubicin-induced senescent cells. The results are as follows Figure 4 Immunofluorescence staining was used to detect changes in γ-H2A.X foci in drug-induced senescent cells. Figure 5 The results showed that when doxorubicin induced hUC-MSCs to undergo premature senescence, the expression level of senescent cell marker p21 protein and γ-H2A.X foci were significantly upregulated.
[0102] Example 4 Validation of the Stress Granule Inducers Screened in hUC-MSCs
[0103] hUC-MSCs cells were seeded onto pre-treated glass slides in 6-well plates. When the number of cells reached 70-80%, some stress granule inducers screened in the model constructed in Example 1 were added to treat the cells for 2 hours, and the cells were observed and photographed under a laser confocal microscope by immunofluorescence staining experiments. The results are shown in Figure 6As shown in the results, sodium arsenite, bardoxolone methyl, plumbagin and zinc pyrithione can induce the formation of stress granules in hUC-MSCs cells to varying degrees, and sodium arsenite and bardoxolone methyl have the most significant effect in inducing stress granules. Therefore, sodium arsenite and bardoxolone methyl were selected as representatives of stress granule inducers to further study the role of stress granule inducers in hUC-MSCs aging.
[0104] Example 5 Inhibitory effect of stress granule inducers on hUC-MSCs aging
[0105] The effects of sodium arsenite and bardoxolone methyl, the hUC-MSCs SGs inducers verified in Example 4, on the hUC-MSCs aging model constructed in Example 2 were investigated.
[0106] When hUC-MSCs cells grew to 60%-70%, they were treated with different concentrations of stress granule inducers, and then induced to senescence using 0.05 μM doxorubicin for 48 hours. After that, the cells were resumed in culture and treated with different concentrations of stress granule inducers again on the 6th day. Samples were collected on the 9th day.
[0107]
[0108] The senescence of hUC-MSCs in each group was detected using the SA-β-gal staining kit. The cells were observed and photographed under a total internal reflection fluorescence microscope, and the number of stained cells in each group was counted. Figure 7 As shown. The results showed that 50μM and 100μM sodium arsenite could significantly delay the senescence of hUC-MSCs induced by doxorubicin, and the CCK8 test found that 50nM-100μM sodium arsenite combined with doxorubicin had no significant cytotoxicity. Similarly, 1.5μM methyl bardoxolone could delay the senescence of hUC-MSCs induced by doxorubicin, and the CCK8 test found that 0.5μM-2μM methyl bardoxolone combined with doxorubicin had no significant cytotoxicity.
[0109] Example 6 Stress granule inducers reduce senescence-related phenotypes in aged hUC-MSCs
[0110] The hUC-MSCs senescent cells in each administration group in Example 4 were used as the research object, and the total protein of each group of cells was extracted. Protein immunoblotting and immunofluorescence staining experiments were used to detect the expression of senescent cell marker cell cycle inhibitor p21 protein and γ-H2A.X foci in hUC-MSCs senescence induced by adriamycin after treatment with SGs inducer sodium arsenite or methyl bardoxolone. The results are as follows Figure 8As shown. The results showed that 100 μM sodium arsenite and 1.5 μM bardoxolone methyl could reduce the elevated p21 expression level and γ-H2A.X foci in doxorubicin-induced senescent hUC-MSCs. In summary, SGs inducers sodium arsenite and methyl bardoxolone can delay doxorubicin-induced hUC-MSCs senescence.
[0111] Example 7 SGs inducers delay hUC-MSCs senescence by sequestering the pro-senescence secretory protein PAI-1
[0112] hUC-MSCs cells were seeded onto pre-treated slides in 6-well plates. When the cells reached 70-80%, the stress granule inducer sodium arsenite was added for 45 minutes or bardoxolone methyl was treated for 2 hours, and the cells were observed and photographed under a laser confocal microscope by immunofluorescence staining. Fig. 9 As shown in the figure, both 100 μM sodium arsenite and 1.5 μM bardoxolone methyl can recruit the pro-senescence secretory protein PAI-1 to stress granules by inducing the formation of stress granules. The sequestration of PAI-1 in stress granules prevents PAI-1 from performing its function of promoting cell senescence, thereby delaying the senescence of hUC-MSCs. In summary, the stress granule inducers sodium arsenite and methyl bardoxolone play a role in delaying the senescence of hUC-MSCs by inducing the formation of stress granules and sequestering the pro-senescence secretory protein PAI-1 in stress granules.
[0113] Example 8 The effect of sodium arsenite and bardoxolone methyl in delaying the aging of hUC-MSCs depends on their SGs inducer function
[0114] The SGs induction of hUC-MSCs by sodium arsenite / methyl bardoxolone in Example 4 was used as the research object, and the SGs inhibitor ISRIB was used in combination. hUC-MSCs were treated with 100 μM sodium arsenite and 200 nM SGs inhibitor ISRIB for 45 minutes, or 1.5 μM methyl bardoxolone and 200 nM SGs inhibitor ISRIB for 2 hours, and then the SGs induction was detected by immunofluorescence staining. The results are shown in Figure 4. Fig.10As shown, the results show that the SGs inhibitor ISRIB can significantly inhibit the formation of SGs in hUC-MSCs induced by SGs inducers sodium arsenite / methyl bardoxolone, indicating that the SGs-inducing function of sodium arsenite / methyl bardoxolone can be blocked by the SGs inhibitor ISRIB. The SGs inducers sodium arsenite / methyl bardoxolone in Examples 5 and 6 were used to delay the aging of hUC-MSCs induced by doxorubicin and reduce aging-related phenotypes, and the SGs inhibitor ISRIB was used in combination. The senescent cell markers of the hUC-MSCs aging model induced by doxorubicin were detected by using a SA-β-gal staining kit and immunofluorescence staining experiments. The results are shown in Fig.10 As shown, the results showed that when the SGs induction function of SGs inducer sodium arsenite / methyl bardoxolone was blocked by SGs inhibitor ISRIB, the effect of SGs inducer sodium arsenite / methyl bardoxolone on delaying doxorubicin-induced hUC-MSCs senescence was weakened, indicating that the effect of sodium arsenite / methyl bardoxolone on delaying doxorubicin-induced hUC-MSCs senescence depends on the function of sodium arsenite / methyl bardoxolone to induce SGs. In summary, the effect of SGs inducer sodium arsenite / methyl bardoxolone on delaying hUC-MSCs senescence depends on the function of SGs inducer.
Claims
1. Application of stress granule inducers in the preparation of umbilical cord mesenchymal stem cell aging inhibitors.
2. The use according to claim 1, characterized in that The stress granule inducer is obtained by screening eukaryotic cells expressing stress granule core proteins G3BP1 and / or G3BP2 carrying detectable tags.
3. The use according to claim 2, characterized in that The detectable label is a fluorescent protein.
4. The use according to claim 3, characterized in that The fluorescent protein is selected from green fluorescent protein, red fluorescent protein or yellow fluorescent protein.
5. The use according to any one of claims 1 to 4, characterized in that The eukaryotic cells expressing the stress granule core proteins G3BP1 and / or G3BP2 carrying detectable labels are prepared by the following method: (1) inserting a G3BP1 or G3BP2 nucleotide fragment carrying a detectable tag into the pSin-EF2 vector to construct an expression plasmid; (2) The expression plasmid is packaged into lentivirus and transfected into eukaryotic cells.
6. The use according to claim 5, characterized in that The eukaryotic cells are HeLa cells, HEK293T cells or U2OS cells.
7. The use according to claim 5, characterized in that The eukaryotic cells are Hela cells. The eukaryotic cells in step (2) are screened and amplified using the lowest lethal concentration of puromycin to obtain a stable cell line.
8. The use according to claim 2, characterized in that The candidate compound is added to the eukaryotic cells expressing the stress granule core protein G3BP1 and / or G3BP2 carrying a detectable label and treated for 1-2 hours, and whether droplet-shaped fluorescent stress granules are formed in the cells is observed by fluorescence microscopy. If the added compound can induce the formation of stress granules, the compound is determined to be a stress granule inducer.
9. The use according to claim 1, characterized in that The stress granule inducer is selected from one or more of sodium arsenite, geldanamycin, shikonin, plumbagin, fingolimod and or zinc pyrithione.
